Артериальная гипертензия

Расширенный поиск

Антигипертензивная терапия в профилактике и коррекции когнитивных расстройств

Полный текст:

Об авторе

А. О. Конради
ФГУ НИИ кардиологии Федерального агентства по здравоохранению РФ; ФГБУ «Федеральный медицинский исследовательский центр имени В.А. Алмазова» Минздрава России

Список литературы

1. Kokmen E. et al. Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc 1996; 71: 275-82.

2. Jorm A.F., Korten A.E., Henderson A.S. The prevalence of dementia: a quantitative Integration of the literature. Acta Psychiatr Scand 1987; 76: 465-79.

3. Fleming К.С. et al. Dementia: Diagnosis end evaluation. Mayo Clin Proc 1995; 70: 1093-107.

4. Roman G. Vascular dementia: Distinguishing characteristics, treatment, and prevention. JAGS 2003; 51: S296-304.

5. Hachinski V.C., Bowler J.V. Vascular dementia. Neurology 1993; 43: 2159-60.

6. Hagnell O., Franck A., Grasbeck A. et al. Vascular dementia in the Lundby study: 1. A prospective, epidemiological study of incidence and risk from 1957-1972. Neuropsychobiology 1992; 26: 43-9.

7. Nyenhuis D.L., Gorelick P.B. Vascular dementia: A contemporary review of epidemiology, diagnosis, prevention and treatment. J Am Geriatr Soc 1998; 46: 1437-48.

8. Selkoe D.J. Alzheimer's disease: Genotypes, phenotype, and treatments. Science 1997; 275: 6З0-1.

9. Hofman A. et al. Atherosclerosis, apolipoprotein E and prevalent of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-4.

10. Stern Y. et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994; 271: 1004-10.

11. Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47: 387-400.

12. Henderson V.W. et al. Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and non-demented control subjects. Arch Neurol 1994; 51: 896-900.

13. Tang M-X et al. Effect of estrogen during menopause on risk' and age at ouset of Alzheimer's disease. Lancet 1996; 348: 429-32.

14. Birge S.J. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc 1996; 44: 865-70.

15. McGeer P.L. et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47; 425-32.

16. Skoog I. et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.

17. Lande M.B., Kaezorwski J.M., Auinger P. et al. Iterated blood pressure and decreased cognitive Junction among school-age children and adolescents in the United States. J Pediatr 2003; 143: 699-700.

18. DeCarli The role of cerebrovascular disease in dementia. Neurologist 2003; 9: 123-36.

19. World Health Organization. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. Geneva: World Health Organization, 1993.

20. Forette F. et al. Prevention of dementia in randomised double-bund placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998; 352: 1347-51.

21. Morich F.J., Bieber F., Lewis J.M. et al. Nimodipine in the treatment of probable Alzhemier's disease: results from tiro randomized trials. Clin Drug Invest 1996; 11: 185-95.

22. Murray M.D., Lane K.A., Gao S. et al. Preservation of cognitive function with antihypertensive medication, a longitudinal analysis of community-based sample of African. Arch Intern Med 2002; 162: 2090-6.

23. Lever A.F., Brennan P.J. MRC trial of treatment in elderly hypertensives. Clin Exp Hypeitens 1993; 15: 941-2.

24. Heart Outcomes Prevention Evaluation (HOPE) study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE sub-study. Lancet 2000; 355: 235-59.

25. PROGESS Collaborative Study Group. Randomised trial period of perindopril based blood pressure loitering regimen among 6108 individuals with previous stroke or transient aschaemic attack. Lancet 2001; 358. 1033-41.

26. Fournier A., Messerly F., Archad J. et al. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent clinical trials. J Am Coll Cardiol 2004; 43: 1343-7.

27. Lindholm L.H., Ibsen T., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End-point Reduction in hypertension study (LIFE). Lancet 2002; 359: 1004-10.

28. Tadesco M.A., Ratti G., Menella G. et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens,. 1999; 12: 1130-4.

29. Lithel H., Hansson L., Skoog I. et al. The study of cognition and prognosis in the elderly (SCOPE). J Hypertension 2003; 21: 875-86.

30. Folstein M.F. et al. "Mini-Mental State". A practical method for grading the cognitive slate of patients for the clinician. J Psychiat Res 1975; 12: 189-98.

31. Schrander J., Luders S., Kulschewski A. et al. Morbidity and mortality after Stroke, eprosaran compared with netrendidpine for secondary prevention (MOSES study). Stroke 2005: 36: 1218-26.

Для цитирования:

Конради А.О. Антигипертензивная терапия в профилактике и коррекции когнитивных расстройств. Артериальная гипертензия. 2005;11(3):160-163.

For citation:

Konradi A.O. Antihypertensive therapy in the prevention and correction of cognitive disorders. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2005;11(3):160-163. (In Russ.)

Просмотров: 398

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)